Abstract
Mitogen-activated protein kinase p38 is a serine/threonine kinase originally isolated from lipopolysaccharide (LPS) stimulated monocytes. There are four isoforms p38α, p38β, p38γ, and p38δ. The most thoroughly studied isoform is p38α, whose activation has been observed in many hematopoietic and nonhematopoietic cell types upon appropriate stimuli. Subsequently, p38α kinase has been shown to be involved in the biosynthesis of TNFα and IL-1β at the translational and transcriptional level. MAP kinase p38agr; represents a point of convergence for multiple signaling processes that are activated in inflammation and thus a key potential target for the modulation of cytokine production. The discovery and publication of p38α and the pyridinyl-imidazole inhibitor initiated a huge effort by many companies to develop p38α inhibitors as potential treatment for inflammatory diseases. Herein we provide a brief overview of recent reported clinical results for AMG 548, BIRB 796, VX 702, SCIO 469, and SCIO 323. However, our focus will be on the binding modes of these inhibitors and other p38 inhibitors in the recent literature.
Keywords: p38 inhibitors, map kinase, tnfα, il-1β, dgf in, dgf out, amg 548, birb 796, scio 469
Current Medicinal Chemistry
Title: MAP Kinase p38Inhibitors: Clinical Results and an Intimate Look at Their Interactions with p38α Protein
Volume: 12 Issue: 25
Author(s): Matthew R. Lee and Celia Dominguez
Affiliation:
Keywords: p38 inhibitors, map kinase, tnfα, il-1β, dgf in, dgf out, amg 548, birb 796, scio 469
Abstract: Mitogen-activated protein kinase p38 is a serine/threonine kinase originally isolated from lipopolysaccharide (LPS) stimulated monocytes. There are four isoforms p38α, p38β, p38γ, and p38δ. The most thoroughly studied isoform is p38α, whose activation has been observed in many hematopoietic and nonhematopoietic cell types upon appropriate stimuli. Subsequently, p38α kinase has been shown to be involved in the biosynthesis of TNFα and IL-1β at the translational and transcriptional level. MAP kinase p38agr; represents a point of convergence for multiple signaling processes that are activated in inflammation and thus a key potential target for the modulation of cytokine production. The discovery and publication of p38α and the pyridinyl-imidazole inhibitor initiated a huge effort by many companies to develop p38α inhibitors as potential treatment for inflammatory diseases. Herein we provide a brief overview of recent reported clinical results for AMG 548, BIRB 796, VX 702, SCIO 469, and SCIO 323. However, our focus will be on the binding modes of these inhibitors and other p38 inhibitors in the recent literature.
Export Options
About this article
Cite this article as:
Lee R. Matthew and Dominguez Celia, MAP Kinase p38Inhibitors: Clinical Results and an Intimate Look at Their Interactions with p38α Protein, Current Medicinal Chemistry 2005; 12 (25) . https://dx.doi.org/10.2174/092986705774462914
DOI https://dx.doi.org/10.2174/092986705774462914 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protein-mediated Fatty Acid Uptake in the Heart
Current Cardiology Reviews Insulin Resistance in the HIV-Infected Population: The Potential Role of Mitochondrial Dysfunction
Current Drug Targets - Infectious Disorders Salt-Sensitive Hypertension: Perspectives on Intrarenal Mechanisms
Current Hypertension Reviews The Regulatory Functions of a New Tetrapeptide from the Bursa of Fabricius on AIV Vaccine Immunization and Antibody Production
Protein & Peptide Letters Quantitative Structure-Activity Relationship Studies on Matrix Metalloproteinase Inhibitors: Hydroxamic Acid Analogs
Medicinal Chemistry Anti-Inflammatory Drug Effects on Apoptosis of Eosinophil Granulocytes Derived from Murine Bone-Marrow: Cellular Mechanisms as Related to Lineage, Developmental Stage and Hemopoietic Environment
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Inflammation, Adiponectin, Obesity and Cardiovascular Risk
Current Medicinal Chemistry Mechanisms of Human Hepatocarcinogenesis
Current Molecular Medicine Anticancer Potential of Ginger: Mechanistic and Pharmaceutical Aspects
Current Pharmaceutical Design Inflammation Markers in Essential Hypertension
Medicinal Chemistry Pharmacological Drug Delivery Strategies for Improved Therapeutic Effects: Recent Advances
Current Pharmaceutical Design SUBJECT INDEX TO VOLUME 1
Current Drug Safety Nursing Assessment, Education, and Care of Extremely Premature Neonates with Patent Ductus Arteriosus
Current Pediatric Reviews New Insights into Vitamin D and Autophagy in Inflammatory Bowel Diseases
Current Medicinal Chemistry New Perspectives in HCV Therapy: Entry Inhibitors
Recent Patents on Anti-Infective Drug Discovery The Role of FLT3 Kinase as an AML Therapy Target
Current Pharmaceutical Design Galactolipids as Potential Health Promoting Compounds in Vegetable Foods
Recent Patents on Food, Nutrition & Agriculture Maintenance Therapy in Multiple Myeloma: Novel Concepts in Clinical Practice from Recent Clinical Trials
Reviews on Recent Clinical Trials CD36 as a Therapeutic Target for Endothelial Dysfunction in Stroke
Current Pharmaceutical Design Supercritical Antisolvent Precipitation of Nimesulide: Preliminary Experiments
Current Drug Delivery